PUMA BIOTECHNOLOGY INC's ticker is PBYI and the CUSIP is 74587V107. A total of 129 filers reported holding PUMA BIOTECHNOLOGY INC in Q2 2020. The put-call ratio across all filers is 2.10 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2020 | $4,000 | 0.0% | 350 | 0.0% | 0.00% | – |
Q2 2020 | $4,000 | +33.3% | 350 | 0.0% | 0.00% | – |
Q1 2020 | $3,000 | -99.0% | 350 | -99.0% | 0.00% | -100.0% |
Q4 2019 | $307,000 | +15250.0% | 35,140 | +25000.0% | 0.00% | – |
Q3 2019 | $2,000 | 0.0% | 140 | 0.0% | 0.00% | – |
Q2 2019 | $2,000 | -60.0% | 140 | 0.0% | 0.00% | – |
Q1 2019 | $5,000 | +66.7% | 140 | 0.0% | 0.00% | – |
Q4 2018 | $3,000 | -50.0% | 140 | 0.0% | 0.00% | – |
Q3 2018 | $6,000 | -50.0% | 140 | -33.3% | 0.00% | – |
Q2 2018 | $12,000 | +9.1% | 210 | +31.2% | 0.00% | – |
Q1 2018 | $11,000 | -47.6% | 160 | -23.8% | 0.00% | – |
Q4 2017 | $21,000 | -16.0% | 210 | 0.0% | 0.00% | – |
Q3 2017 | $25,000 | +38.9% | 210 | 0.0% | 0.00% | – |
Q2 2017 | $18,000 | +200.0% | 210 | +31.2% | 0.00% | – |
Q1 2017 | $6,000 | -33.3% | 160 | -46.7% | 0.00% | – |
Q4 2016 | $9,000 | 0.0% | 300 | 0.0% | 0.00% | – |
Q1 2016 | $9,000 | – | 300 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Athyrium Capital Management, LP | 1,792,114 | $4,713,260 | 4.15% |
Eversept Partners, LP | 1,681,149 | $4,421,422 | 0.37% |
Camber Capital Management LP | 4,235,000 | $11,138 | 0.37% |
Kynam Capital Management, LP | 473,975 | $1,246,554 | 0.20% |
GLOBEFLEX CAPITAL L P | 538,559 | $1,416,410 | 0.17% |
Affinity Asset Advisors, LLC | 202,349 | $532,178 | 0.15% |
GSA CAPITAL PARTNERS LLP | 279,629 | $735 | 0.06% |
RICE HALL JAMES & ASSOCIATES, LLC | 363,666 | $956,442 | 0.06% |
Patriot Financial Group Insurance Agency, LLC | 67,000 | $176,210 | 0.04% |
ACADIAN ASSET MANAGEMENT LLC | 1,858,000 | $4,884 | 0.02% |